1157 related articles for article (PubMed ID: 17762437)
1. Can serum markers be used to predict acute and late toxicity in patients with lung cancer? Analysis of RTOG 91-03.
Hartsell WF; Scott CB; Dundas GS; Mohiuddin M; Meredith RF; Rubin P; Weigensberg IJ
Am J Clin Oncol; 2007 Aug; 30(4):368-76. PubMed ID: 17762437
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and outcome results of RTOG 9311: a phase I-II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non-small-cell lung carcinoma.
Bradley J; Graham MV; Winter K; Purdy JA; Komaki R; Roa WH; Ryu JK; Bosch W; Emami B
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):318-28. PubMed ID: 15667949
[TBL] [Abstract][Full Text] [Related]
3. Time course of serum cytokines in patients receiving proton or combined photon/proton beam radiation for resectable but medically inoperable non-small-cell lung cancer.
Gridley DS; Bonnet RB; Bush DA; Franke C; Cheek GA; Slater JD; Slater JM
Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):759-66. PubMed ID: 15465192
[TBL] [Abstract][Full Text] [Related]
4. Predictive factors of late radiation fibrosis: a prospective study in non-small cell lung cancer.
Mazeron R; Etienne-Mastroianni B; Pérol D; Arpin D; Vincent M; Falchero L; Martel-Lafay I; Carrie C; Claude L
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):38-43. PubMed ID: 20171801
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and outcome results of a class solution with moderately hypofractionated radiotherapy in inoperable Stage III non-small cell lung cancer using helical tomotherapy.
Bral S; Duchateau M; Versmessen H; Engels B; Tournel K; Vinh-Hung V; De Ridder M; Schallier D; Storme G
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1352-9. PubMed ID: 20056350
[TBL] [Abstract][Full Text] [Related]
6. [Effort to radically cure stage III and IV esophageal carcinoma with simultaneous radiotherapy and chemotherapy in standard clinical practice].
Farzad M; De Luca MC; Rubino G; Pirtoli L; Pepi F; Sebaste L; Ponticelli P; Atzeni G; Maranzano E; Silvano G
Radiol Med; 2001; 102(1-2):72-7. PubMed ID: 11677442
[TBL] [Abstract][Full Text] [Related]
7. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis.
Claude L; Pérol D; Ginestet C; Falchero L; Arpin D; Vincent M; Martel I; Hominal S; Cordier JF; Carrie C
Radiother Oncol; 2004 May; 71(2):175-81. PubMed ID: 15110451
[TBL] [Abstract][Full Text] [Related]
8. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.
Rosenzweig KE; Fox JL; Yorke E; Amols H; Jackson A; Rusch V; Kris MG; Ling CC; Leibel SA
Cancer; 2005 May; 103(10):2118-27. PubMed ID: 15830346
[TBL] [Abstract][Full Text] [Related]
9. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan.
Zhao L; Wang L; Ji W; Wang X; Zhu X; Hayman JA; Kalemkerian GP; Yang W; Brenner D; Lawrence TS; Kong FM
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1385-90. PubMed ID: 19231104
[TBL] [Abstract][Full Text] [Related]
10. An accelerated radiotherapy scheme using a concomitant boost technique for the treatment of unresectable stage III non-small cell lung cancer.
Izmirli M; Yaman F; Buyukpolat MY; Yoney A; Unsal M
Jpn J Clin Oncol; 2005 May; 35(5):239-44. PubMed ID: 15886271
[TBL] [Abstract][Full Text] [Related]
11. Small-volume image-guided radiotherapy using hypofractionated, coplanar, and noncoplanar multiple fields for patients with inoperable Stage I nonsmall cell lung carcinomas.
Fukumoto S; Shirato H; Shimzu S; Ogura S; Onimaru R; Kitamura K; Yamazaki K; Miyasaka K; Nishimura M; Dosaka-Akita H
Cancer; 2002 Oct; 95(7):1546-53. PubMed ID: 12237924
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer.
Zimmermann FB; Geinitz H; Schill S; Grosu A; Schratzenstaller U; Molls M; Jeremic B
Lung Cancer; 2005 Apr; 48(1):107-14. PubMed ID: 15777977
[TBL] [Abstract][Full Text] [Related]
13. Escalated dose for non-small-cell lung cancer with accelerated hypofractionated three-dimensional conformal radiation therapy.
Thirion P; Holmberg O; Collins CD; O'Shea C; Moriarty M; Pomeroy M; O'Sullivan C; Buckney S; Armstrong J
Radiother Oncol; 2004 May; 71(2):163-6. PubMed ID: 15110449
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study.
Baumann P; Nyman J; Hoyer M; Gagliardi G; Lax I; Wennberg B; Drugge N; Ekberg L; Friesland S; Johansson KA; Lund JS; Morhed E; Nilsson K; Levin N; Paludan M; Sederholm C; Traberg A; Wittgren L; Lewensohn R
Radiother Oncol; 2008 Sep; 88(3):359-67. PubMed ID: 18768228
[TBL] [Abstract][Full Text] [Related]
15. Effects of rhubarb extract on radiation induced lung toxicity via decreasing transforming growth factor-beta-1 and interleukin-6 in lung cancer patients treated with radiotherapy.
Yu HM; Liu YF; Cheng YF; Hu LK; Hou M
Lung Cancer; 2008 Feb; 59(2):219-26. PubMed ID: 17870203
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
Jiang ZQ; Yang K; Komaki R; Wei X; Tucker SL; Zhuang Y; Martel MK; Vedam S; Balter P; Zhu G; Gomez D; Lu C; Mohan R; Cox JD; Liao Z
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):332-9. PubMed ID: 22079735
[TBL] [Abstract][Full Text] [Related]
17. The predictive role of plasma TGF-beta1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer.
Zhao L; Sheldon K; Chen M; Yin MS; Hayman JA; Kalemkerian GP; Arenberg D; Lyons SE; Curtis JL; Davis M; Cease KB; Brenner D; Anscher MS; Lawrence TS; Kong FM
Lung Cancer; 2008 Feb; 59(2):232-9. PubMed ID: 17905467
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients.
Novakova-Jiresova A; Van Gameren MM; Coppes RP; Kampinga HH; Groen HJ
Radiother Oncol; 2004 May; 71(2):183-9. PubMed ID: 15110452
[TBL] [Abstract][Full Text] [Related]
19. Significance of plasma transforming growth factor-beta levels in radiotherapy for non-small-cell lung cancer.
De Jaeger K; Seppenwoolde Y; Kampinga HH; Boersma LJ; Belderbos JS; Lebesque JV
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1378-87. PubMed ID: 15050313
[TBL] [Abstract][Full Text] [Related]
20. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
